PhRMA Statement on Patent Reform

Washington, D.C. (February 2, 2011) — The Pharmaceutical Research and Manufacturers of America Senior Vice President Wes Metheny today released the following statement:

Emerging Biopharmaceutical Companies: Ensuring a Favorable Environment for Continued Innovation

PhRMA Statement Regarding Translational Research

Washington, D.C. (Jan. 23, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President David E. Wheadon issued the following statement today regarding public/private collaborations in new drug discovery:

“Collaboration – including industry, NIH and academia – is one element driving innovation in drug development, particularly early stage – and ‘bold and ambitious’ proposals, such as Dr. Collins’, will be key to how we collectively progress in discovering novel compounds for addressing patients’ unmet medical needs.

PhRMA Statement on Personalized Medicine Research

Washington, D.C. (November 16, 2010) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Wes Metheny issued the following statement today regarding the Tufts Center for the Study of Drug Development Impact Report on personalized medicine research:

PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy

Washington, D.C. (November 3, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani released the following statement and video

PhRMA Comments on the 2010 Special 301 Report

Washington, D.C. (May 3, 2010) — Pharmaceutical Research and Manufacturers of America President, International, Christopher Singer issued the following statement today on the U.S. Trade Representative’s (USTR) "Special 301" annual report to Congress, outlining the Administration’s global intellectual property agenda:

PhRMA Statement on Patent Reform Agreement

Washington, D.C. (March 5, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today about a recent patent reform agreement reached by Members of Congress:

PhRMA Statement on Partnership to Support Innovation

Washington, D.C. (February 24, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding efforts to encourage medical progress:

PhRMA Applauds Outcome of US-Israel Intellectual Property Agreement

Washington, D.C. (February 18, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) President, International, Christopher Singer issued the following statement on the completion of the U.S.-Israel Special 301 Out-of-Cycle Review:

PhRMA Statement on Intellectual Property

Washington, D.C. (February 16, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today regarding the Department of Justice Task Force on Intellectual Property:

Pages

Subscribe to RSS - Innovation